DBVT - Viaskin peanut allergy therapy fallout continues as DBV down another 16% today

DBV Technologies (DBVT -17.8%), which announced after the bell Tuesday that the FDA has requested more data on its peanut allergy therapy Viaskin, is down even further today. Shares fell ~29% between the close of trading Tuesday and the closing bell yesterday. DBV said that a planned trial for Viaskin would not begin until its receives complete feedback from the FDA. DBV's only other clinical candidate is Viaskin Milk for cow's milk protein that is in phase 2. On Tuesday, DBV also released its Q3 2021 earnings.

For further details see:

Viaskin peanut allergy therapy fallout continues as DBV down another 16% today